
United States · Research startup
IconOVir Bio is a biotechnology company based in San Diego, California, founded in 2018.
Funding reportedLast round: Series A
IconOVir Bio is a biotechnology company based in San Diego, California, founded in 2018.
The company specializes in developing oncolytic virus therapies aimed at treating cancer, particularly solid tumors and advanced cancers. Its core platform is a proprietary oncolytic virus system, developed from research by Dr. Clodagh O’Shea at the Salk Institute, designed to enhance personalized cancer therapy. The lead candidate from IconOVir Bio is ICVB-1042, which is administered intravenously and is currently in a Phase 1 clinical trial for advanced solid tumors, having started in July 2023. The company is focused on research and development, working on differentiated oncolytic virus candidates that exhibit tumor selectivity and broad tumor-cell infectivity, targeting patients with cancer and the oncology treatment community.
Funding, as reported
From the SEC filings it signed: 9 on the team.
On the board, as filediHelen S. KimJakob S. LovenWilliam S. Kaelin
What they build
Known for
health carebiotechnology researchmedical researchbiotech researchclinical researchhospital & health carecancer immunotherapymedicalcancer treatmenthealthbiotechnologyoncology biotechdrug developmentresearch and development in the physicalengineeringbiotech
Built with from their website
WordPress.orgFont AwesomeElementorViewport MetaHello ElementorKnowBe4SucuriMicrosoft ExchangeMySQLMicrosoft 365 Apps & Services
Mobile FriendlyOpen GraphjQueryRSSYoast SEOZoom MeetingsYoastZendesk for Service
Add your raise, your deck and your story, and put IconOVir Bio in front of investors. Or tell us what we have wrong.